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Abstract
Regulation of the extracellular matrix (ECM) plays an important functional role either in physiological or pathological
conditions. The plasminogen activation (PA) system, comprising the uPA and tPA proteases and their inhibitor PAI-1, is one
of the main suppliers of extracellular proteolytic activity contributing to tissue remodeling. Although its function in
development is well documented, its precise role in mouse embryonic stem cell (ESC) differentiation in vitro is unknown.
We found that the PA system components are expressed at very low levels in undifferentiated ESCs and that upon
differentiation uPA activity is detected mainly transiently, whereas tPA activity and PAI-1 protein are maximum in well
differentiated cells. Adipocyte formation by ESCs is inhibited by amiloride treatment, a specific uPA inhibitor. Likewise, ESCs
expressing ectopic PAI-1 under the control of an inducible expression system display reduced adipogenic capacities after
induction of the gene. Furthermore, the adipogenic differentiation capacities of PAI-12/2 induced pluripotent stem cells
(iPSCs) are augmented as compared to wt iPSCs. Our results demonstrate that the control of ESC adipogenesis by the PA
system correspond to different successive steps from undifferentiated to well differentiated ESCs. Similarly, skeletal
myogenesis is decreased by uPA inhibition or PAI-1 overexpression during the terminal step of differentiation. However,
interfering with uPA during days 0 to 3 of the differentiation process augments ESC myotube formation. Neither
neurogenesis, cardiomyogenesis, endothelial cell nor smooth muscle formation are affected by amiloride or PAI-1 induction.
Our results show that the PA system is capable to specifically modulate adipogenesis and skeletal myogenesis of ESCs by
successive different molecular mechanisms.
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Introduction
Adipose, vascular and muscle tissue plasticity occurs in a number
of normal and physiopathological processes including embryonic
development, adult muscle aging, muscular dystrophies, obesity
and diabetes. There is ample evidence both in vivo and in vitro that
the extracellular matrix (ECM) surrounding the tissues plays an
important functional biological role either in physiological or
pathological conditions. Likewise its function in development is
well documented, suggesting that ECM could be involved in the
regulation of the commitment and differentiation of stem cells.
The concept of niche in which the stem cell fate is dependent on
interactions with its surrounding environment represents a para-
digm of these regulations [1,2].
The PA system is one of the main suppliers of extracellular
proteolytic activity, such as the fibrinolysis, thus contributing to
ECM degradation and tissue remodelling. It is exerted by two
distinct plasminogen activators, tPA (tissue-type plasminogen
activator) and uPA (urokinase-type plasminogen activator) [3,4].
The plasminogen activator inhibitor-1 (PAI-1) directly inhibits the
proteolytic activity of uPA and tPA [3]. This system is implicated
in numerous fibrinolytic and non-fibrinolytic processes leading to
either ECM degradation, activation of latent growth factors, or
integrin-mediated cell adhesion on vitronectin (VN) [5,6]. All these
processes are inhibited by PAI-1 [7,8]. In vitro, PAI-1 regulates
adipocyte differentiation [9] and, by controlling endothelial cell
migration and prolifereation, is a potent regulator of angiogenesis
[10,11,12]. Finally, PAI-1 interferes with myogenesis: myogenic
cells express the proteins of the plasminogen activation system
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[13,14] and uPA is able to stimulate proliferation, migration and
fusion of satellite cells, whereas uPA inhibition abrogated
myogenesis [15]. In addition, genetic approaches demonstrated
that uPA, but not tPA, activity is required for efficient skeletal
muscle regeneration in vivo [16] and that this process is
accelerated in PAI-1-deficient mice [17].
However the precise role of the PA system and more generally
the role of ECM during the development and the commitment of
pluripotent cells in in vitro experimental models such as the
differentiation of Embryonic Stem Cells (ESCs) are still poorly
known. ESCs are pluripotent and can be induced to differentiate
into a variety of cell types [18]. Transplantation of ESCs has been
proposed as a future therapy for various human diseases. However
only variable fractions of cells reaches the desired differentiated
phenotype, therefore their therapeutic use necessitates a better
understanding of the molecular mechanisms that control their
commitment. Self-renewal of ESCs is dependent on a complex
interplay between specific stimuli (for example, the growth factor
LIF for mouse ESCs) specific epigenetic processes, miRNAs and
transcription factors involved in the development of the embryo.
Appropriate culture conditions result in their commitment into
mature differentiated cell types (see for reviews [18,19,20]). In
order to approach the potential regulatory role of extracellular
matrix, we studied the plasminogen activation (PA) system during
ESC differentiation.
We found that the PA system components are expressed at very
low levels in undifferentiated ESCs and that upon differentiation
uPA activity is detected mainly transiently, whereas tPA activity
and PAI-1 protein are maximum in well differentiated cells. We
then characterized the role of the PA system in ESC differentiation
by different approaches and found that interfering with uPA
activity leads, on the one hand, to inhibition of adipogenesis and,
on the other hand, to positive and negative regulations of skeletal
myogenesis by successive different molecular mechanisms.
Materials and Methods
Differentiation of ESCs
CGR8 mouse ESCs [21] were grown on gelatin-coated plates
and A2lox.cre ESCs [22] were grown on MEF feeders treated with
10 mg/ml mitomycin C for 3 hours. 16103 ESCs were aggregated
without LIF to form embryoid bodies (EB) at day 0, cultivated in
suspension until day 7, treated or not with 1027 M All-Trans
Retinoic Acid (Sigma, France) daily between days 3 to 5, plated at
day 7 on gelatin-coated 6-well plate and treated with 85 nM
insulin (Sigma, France), 2 nM 3,39,5-tri-iodothyronine (Sigma,
France) to induce terminal differentiation. Fresh medium contain-
ing the inducers was applied every 2 days. EBs were analyzed for
cardiomyocytes, endothelial cells or neurons at day 12, and
adipocytes or myotubes at day 26, as described previously
[21,23,24]. 100 mmol/L of the uPA inhibitor Amiloride (Sigma,
France) or 0.5 mg/ml of doxycycline (Sigma, France) were added
to the culture media at different period of time as indicated.
Plasmid and Generation of ESC Lines
After addition of two HindIII sites, the human PAI-1 cDNA
isolated from the PIGE20-hPAI-1-stable [25] was inserted into the
p2Lox [22], generating the p2Lox-PAI-1 plasmid. The A2lox.cre
ESC line was electroporated with 2 mg of p2Lox-hPAI-1 (Amaxa
Biosystems, A24 program for ESC), according to the manufac-
turer’s protocol, and selected with 500 mg/ml G418 (PAA,
France). Transfection was realized onto mitomycin C-treated
stable neomycin resistant MEF feeder cells obtained by trans-
duction with the CHC-vector, a MLV retrovirus-vector coding the
Neo cDNA using an MOI of 6 UI/cell, followed by Neomycin
selection (100 mg/ml) as described previously [26].
Generation of iPSCs
16105 wt or PAI-12/2 MEFs [27] cultivated in DMEM
supplemented with 10% fetal bovine serum were infected, at
30xMOI, with the KOSM polycistronic lentivirus vector encoding
the murine transcriptor factors Klf4, Oct4, Sox2 and Myc [28].
The day after, medium was changed for the ESC medium.
Colonies presenting an ESC phenotype were visible after 2 weeks
and picked at day19.
RNA analysis
Total RNA was prepared using Trizol reagent (Invitrogen,
France). Real time Reverse Transcriptase-PCR was performed
with the ABI Prism7300 (Applied BioSystems, France) and Mesa
Green MasterMix (Eurogentec, France). The relative amounts of
the different mRNAs were quantified by using the comparative
CT method (2-(DDCT)). 36B4 was used as housekeeper transcripts
and gene expressions were normalized using 36B4 RNA levels.
Primer sequences are given in Data S12.
Western Blot Analysis
ESCs were lysed as described [21] at days 0 (for Oct4 analysis)
or 24 (for MyH1) of the differentiation protocol. Samples at day
0 (20 mg) were separated by SDS-polyacrylamide gel electropho-
resis on a 10% gel (Invitrogen, France), transferred onto
polyvinylidene difluoride membranes (Millipore, France) and
incubated with antibodies against Oct-4 (1:1000, Abcam, France)
or ERK (1:2000, Santa Cruz, California, USA). Samples at day 24
(20 mg) were separated by SDS-polyacrylamide gel electrophoresis
on a 3–8% gel (Invitrogen, France), transferred onto polyvinyli-
dene difluoride membranes (Millipore, France) and incubated with
antibodies against Myosin (MF20) (1:500, DSHB, Iowa City, USA)
or ERK.
Immunocytochemistry, Immunofluorescence and Oil Red
O Staining
For PAI-1 immunocytochemistry studies, cells were washed
at day 24, fixed in 4% paraformaldehyde for 15 min at room
temperature (RT), permeabilized in PBS-0.2% Triton X-100 for
15 min at RT, blocked by serum for 30 min, and then incubated
with 23.4 mg/ml rabbit anti-mouse PAI-1 (H34G6D10, provided
by Dr P. Declerck) for 1 h. After rinsing twice with PBS, anti-
rabbit IgG secondary antibody (Vector, UK) was added, incubated
for 40 min, followed by two washes in PBS, incubated with
vectastain ABC (Vector, UK) for 30 min, washed with PBS, and
stained with DAB (Dako, France). Slides were counterstained with
hematoxylin (1:2 dilution in distilled water).
For MyH1 immunofluorescence studies, fixed cells at day
24 were permeabilized in PBS-0.2% Triton X-100 for 15 min at
RT and incubated with anti-Myosin (MF20) (DSHB, Iowa City,
USA) in PBS-10% FBS for 2 hours. After three washes in PBS,
cells were incubated with anti-mouse ALEXA488 (Invitrogen,
France) for 1 hour at RT.
For ECM characterization, cell cultures were first
acellularized by using a cultured cells Acellularization kit
(Sigma, France). Briefly, EBs at days 12 and 24 were incubated
for 10 min with the Acellularization buffer and gently shaked at
RT. After carefully aspirating the Acellularization buffer,
cultures were carefully rinsed twice with PBS. The ECM was
then incubated with anti-Collagen I (1:100, Abcam, France) in
PBS-1% BSA for 2 hours at RT. After three washes in PBS,
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ECM was incubated with anti-rabbit ALEXA468 (Invitrogen,
France) for 1 hour at RT.
For iPSC characterization, fixed cells at day 0 were
permeabilized in PBS-0.2% Triton X-100 for 15 min at RT and
incubated with either anti-SSEA1 (MC480) (DSHB, Iowa City,
USA), anti-Sox2 (AB5603) (Millipore, France), anti-Oct4
(ab19857) (Abcam, France), or anti- Nanog (SC30328) (Santa
Cruz Biotechnology, California, USA) in PBS-10% FBS for 2
hours. After three washes in PBS, cells were incubated with either
anti-mouse ALEXA488 (Invitrogen, France), anti-rabbit
ALEXA468 (Invitrogen, France), or anti-goat ALEXA568 (In-
vitrogen, France) for 1 hour at RT.
For Oil Red O Staining, fixed cells at day 24 were immersed
30 min at RT in a solution of Oil Red O [29], and then washed
5 times with deionised water.
Flow Cytometry
Cells were trypsinized, washed with 10%FBS/DMEM, fixed in
0,5% paraformaldehyde for 15 min at room temperature (RT)
and permeabilized with 0.1% Triton/PBS buffer for 10 min at
RT. Cells were then stained with an a-Myogenin (FD5) antibody
at 1:10 dilution in 5%FBS/PBS (DSHB, Iowa City, USA) for
1 hour under agitation, washed with 5%FBS/PBS, and incubated
with an anti-mouse IgG secondary antibody conjugated to PE
(1:100 dilution in 5%FBS/PBS) (Beckman Coulter, France) for
30 min under agitation. After additional washes in PBS, cells were
resuspended in 500 ml PBS and analyzed on a FC500 Flow
cytometer using CXP software (Beckman Coulter, France). For
each sample, at least 5000 cells were analyzed. Cursor for positive
fluorescent cell determination was placed, such as 75% of events
were outside (first decade) the cursor region when an isotype IgG
antibody was used. Results are given as percentage corresponding
to positive fluorescent cells included in the region defined by the
cursor and after subtracting the irrelevant’s percentage.
ELISA Assays
Murine uPA and tPA antigens were quantified using
respectively the MUPAKT-TOT and MTPAKT-TOT immuno-
assay kits from Gentaur, France, according to supplier’s
recommendations. A standard calibration curve was prepared
using dilutions of purified uPA from 0.025 to 2 ng/ml and of
purified tPA from 0 to 50 ng/ml.
Murine uPA and tPA activities were quantified using
respectively the MUPAKT and MTPAKT immunoassay kits from
Gentaur, France, according to supplier’s recommendations. A
standard calibration curve was prepared using dilutions of purified
uPA from 0.025 to 2 ng/ml and of purified tPA from 0 to 50 ng/
ml.
Human and mouse PAI-1 antigens were quantified by
immunoassays, wells of microtiter plates were coated overnight at
4uC with 2 mg/ml human PAI-1 antibody (15H12, provided by Dr
P. Declerck), or 48 h at 4uC with 2 mg/ml rabbit anti-mouse PAI-
1 (H34G6D10 provided by Dr P. Declerck), washed with PBS
0,004% Tween 80, and blocked for 2 h with a solution of 1% BSA
in PBS. Cell lysates, diluted five times, or undiluted conditioned
media, prepared from 24 hours cell supernatants cultivated
without serum, were added to each well and incubated overnight
at 4uC. After four washes with PBS 0,004% Tween 80,
biotinylated anti-mPAI-1 antibody Ra-mPAI-1(1:800) was added
for 1 h at RT, and for another hour with vectastain ABC (Vector,
UK), or anti-human antibody 12A4A6 (1:800) was added for 2 h
at RT. After four washes with PBS 0,004% Tween 80, ultra-TMB
solution (Thermo scientific, France) was added. The reaction was
stopped by adding H2SO4 (2M final concentration), and the
optical density was read at 450 nm. A standard calibration curve
was prepared using dilutions of purified PAI-1 from 0 to 10 ng/
ml.
Human PAI-1 activity was quantified by using the Zymutest
PAI-1 Activity immunoassay kit (HYPHEN Biomed, France);
according to supplier’s recommendations. A standard calibration
curve was prepared using dilutions of purified PAI-1 from 0 to
20 ng/ml.
Teratoma Formation and Histological Analyses
CGR8 ESCs, and wt and PAI-12/2 iPSCs were trypsinized and
washed, and 56106 cells resuspended in 200 ml of PBS were
injected subcutaneously into both sides of the back of 6-week-old
athymic nude female mice (Harlan, France). At 5 weeks following
injection, tumours were surgically excised, fixed in formalin,
paraffin-embedded, and 5 mm thick sections were analyzed and
photographed after hematoxylin–eosin staining.
Statistical Analyses
All experiments were performed at least three times. All data are
expressed as the mean 6SEM. Treatments were compared with
their respective controls and significant differences among the
groups were determined using unpaired Student’s t-test. A value of
p,0.05 was taken as an indication of statistical significance.
Results
Gene Expression of uPA, tPA,uPAR and PAI-1 before and
after ESC Differentiation
Mouse ESCs are differentiated by removing the LIF from the
medium and forming aggregates in suspension, called embryoid
bodies (EBs), for one week. After this crucial commitment phase,
cells are allowed to terminally differentiate by replating EBs on
Petri dishes. This experimental protocol leads to the spontaneous
formation, into the same culture dishes and in function of time, of
several well-differentiated cells from a fraction of the starting ESC
population. Neuron and adipocyte formation necessitates a critical
early three days treatment of EBs between days 3 to 5 of the
protocol with retinoic acid (hereafter referred as RA or adipogenic
conditions); conversely, not treated RA EBs will form spontane-
ously endothelial cells, cardiomyocytes, and smooth and skeletal
myogenic cells (hereafter referred as NoRA or myogenic
conditions). Routinely, at day 12 of differentiation, we followed
neurogenesis by the expression of the neuronal marker MAP2;
endothelial cell differentiation by the expression of Flk-1, PECAM
and von Villebrand Factor (vWF) genes; smooth muscle cells by
the alpha-smooth muscle actin (a-SMA) marker; and cardiomyo-
genesis by the TroponinT and GATA4 markers. At day 24 of
differentiation, we followed adipogenesis by the expression of aP2,
PPARgamma and adiponectin genes and skeletal myogenesis by
the Myogenin and Myosin heavy Chain-1 (MyH1) markers
[26,30,31].
mRNAs, proteins and enzymatic activities of uPA and tPA
have been analyzed by quantitative RT-PCR and ELISA
techniques at various times during the differentiation of CGR8
mouse ESCs. uPA and tPA expressions and activities are almost
undetectable in undifferentiated ES cells (Fig. 1 and 2). Upon
differentiation, with or without RA treatment, uPA mRNA
expression increases gradually, reaching a maximum at day 14
(Fig. 1A). A similar expression profile is found for uPA proteins
in cell supernatants, except for the NoRA myogenic condition
where it continues to augment till day 24 (Fig. 1B). In-
terestingly, uPA activities in supernatants, although following an
identical profile until day 14, are then lower. This latter
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enzymatic inhibition could be due to the presence of high
amounts of PAI-1 proteins during this period (Fig. 3B).
Intracellular uPA protein and activity are detected only
transiently during the differentiation process, at days 3 and 7,
being almost undetectable by day 14 (Fig. 1C).
Figure 1. endogenous uPA mRNA, protein expression and enzymatic activities during ESC differentiation. Retinoic acid-treated (RA) or
not (NoRA) EBs from wild type CGR8 ESCs were induced to differentiate and analyzed at various time, as indicated, between days 0 (d0) to 24 (d24).
(A) mRNAs were extracted and analyzed by real time RT-PCR for the expression of uPA. Results are expressed in arbitrary units, with the values of wild
type CGR8 at day 0 taken as 1, and are the means 6 S.E.M. of at least 3 independent experiments. Significance is given as: *P,0.05, **P,0.01 and
***P,0.001. (B and C) uPA antigen (upper panels) or specific uPA enzymatic activity (lower panels) were quantified by ELISA technique in either total
cell lysate protein extracts (B) or in 24 hr. conditioned medium of cells cultivated without serum (C). Mean values of at least three independent
experiments are given.
doi:10.1371/journal.pone.0049065.g001
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Upon differentiation, with or without RA treatment, tPA
protein expression in supernatants and tPA mRNAs increase
gradually, reaching a maximum at day 24 (Fig. 2A and B). tPA
activities in supernatants, although globally following an identical
profile to uPA activities do not decrease significantly after day 14,
staying at high levels until day 24. Intracellular tPA protein and
Figure 2. endogenous tPA mRNA, protein expression and enzymatic activities during ESC differentiation. Retinoic acid-treated (RA) or
not (NoRA) EBs from wild type CGR8 ESCs were induced to differentiate and analyzed at various time, as indicated, between days 0 (d0) to 24 (d24).
(A) mRNAs were extracted and analyzed by real time RT-PCR for the expression of tPA. Results are expressed in arbitrary units, with the values of wild
type CGR8 at day 0 taken as 1, and are the means 6 S.E.M. of at least 3 independent experiments. Significance is given as: *P,0.05, **P,0.01 and
***P,0.001. (B and C) tPA antigen (upper panels) or specific tPA enzymatic activity (lower panels) were quantified by ELISA technique in either total
cell lysate protein extracts (B) or in 24 hr. conditioned medium of cells cultivated without serum (C). Mean values of at least three independent
experiments are given.
doi:10.1371/journal.pone.0049065.g002
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activity are detected from days 3 to 24, reaching a maximum at
day 3 and then slightly decreasing (Fig. 2C).
Expression of PAI-1 (mRNA and protein) is almost undetectable
in undifferentiated cells and till day 7 and correlates mainly with
terminal adipocyte and skeletal myogenic differentiations (Fig. 3).
Interestingly, at day 24 of the differentiation, PAI-1 expression is
significantly higher in cultures without RA treatment than in RA-
treated embryoid bodies, suggesting that PAI-1 expression could
be higher in skeletal myotubes than in adipocytes. Since these
cultures are not pure differentiated cell populations, one could
hypothesize that PAI-1 would not be expressed in adipocytes.
Therefore, we analyzed the expression of PAI-1 by immunocyto-
chemistry at day 24 in well differentiated cells. In all tested
conditions, we were able to detect PAI-1 protein in both
adipocytes and myotubes (Data S1).
Variations of expression of the receptor of uPA, uPAR, are very
limited during the differentiation process (data not shown).
Altogether these results show that uPA activity is mainly present
during the early d0–d14 period, whereas tPA activity is still
strongly detected in well differentiated cells; PAI-1 protein is
present only in the latter steps of differentiation, from d14 to d24.
uPA Inhibition by Amiloride Decreases ESC Adipogenesis
These striking regulations of endogenous components of the PA
system during ESC differentiation suggested important biologic
roles for these molecules. In order to analyze their regulatory
potential, we treated ESCs with amiloride, a potent specific
chemical uPA inhibitor which does not affect the tPA protease
[32]. Because the first week of the differentiation process is critical
for the ESC commitment [26], 100 mM of the inhibitor were
applied on CGR8 ESCs in four different conditions: i) all the time
of differentiation, from days 0 to 24 [A], ii) only from days 0 to 3
[A(d0–d3)], iii) from days 3 to 7 [A(d3–d7)], iv) from days 7 to
24 [A(d7–d24)] (Fig. 4A). The inhibitory effect of amiloride on
uPA enzymatic activity was measured between days 0 to 14 of the
differentiation process. Whereas uPA activity is very low in control
undifferentiated cells, this activity augments as early as day 3,
reaching a maximum, at day 7 into the 24 hrs conditioned
medium of RA-treated (adipogenic conditions) or not (skeletal
myogenic conditions) cells, respectively (Fig. 4B and C, black
curves). These activities are completely inhibited by the amiloride
treatment all the time of differentiation, (red curves), inhibition at
day 14 is also observed when amiloride is added at day 7 (blue
curves). Interestingly, when amiloride is added only between days
0 to 3, uPA activity is inhibited at day 3 but is fully recovered at
days 7 and 14 (green curves). Likewise, when amiloride is added
between days 3 to 7, uPA activities decrease during this period and
are partially recovered by day 14 (violet curves). Importantly, these
results demonstrate that the uPA inhibition by amiloride is
a reversible process. Although close to the detection limit of the
assay, similar results were obtained by analyzing uPA activity in
cellular lysates (Data S2).
We then analyzed the effects of the inhibitor on ESC
differentiation. All amiloride treatments of CGR8 cells signifi-
cantly decrease by more than 60% the expression of adipogenic
markers measured at day 24: adiponectin (Fig. 4D), aP2 (Fig. 4E)
and PPARgamma (Fig. 4F). These inhibitions of adipocyte
formation resulted in less lipids accumulated in cell cultures, as
detected by Oil RedO staining (Fig. 4G). As a control, we found
no effect on cells treated with di-methyl-amiloride, an amiloride-
derived compound which no longer inhibits uPA (data not shown).
Since uPA activities are detected at least until day 14, these results
suggest that uPA plays important successive roles during the whole
process of ESC adipogenesis.
In order to check whether the amiloride treatment could affect
the extracellular matrix (ECM) secreted by ESCs during the
differentiation process, we characterized the collagen 1 ECM
composition by immunofluorescence studies after acellularization
of the cultures at days 12 and 24. Collagen 1 is detected in low
amounts at day 12 of differentiation in control cells, treated (Data
S3) or not (Data S4) by RA and its expression is slightly
augmented by day 24. Interestingly, the amiloride treatment
A(d0–d24) strongly increases collagen 1 deposition at day 24 in
both RA and NoRA treated cells and this increase is visible as soon
Figure 3. endogenous PAI-1 mRNA and protein expression
during ESC differentiation. Retinoic acid-treated (RA) or not (NoRA)
EBs from wild type CGR8 ES cells were induced to differentiate and
analyzed at various time, as indicated, between days 0 (d0) to 24 (d24).
(A) mRNAs were extracted and analyzed by real time RT-PCR for the
expression of PAI-1. Results are expressed in arbitrary units, with the
values of wild type CGR8 at day 0 taken as 1, and are the means 6
S.E.M. of at least 3 independent experiments. Significance is given as:
*P,0.05, **P,0.01 and ***P,0.001. (B and C) PAI-1 protein expression
in total cell lysates (B) or conditioned medium (C) was quantified by
ELISA technique at various time, as indicated, between days 0 (d0) to 24
(d24). Values are given in ng of PAI-1 amounts and expressed as means
of at least three independent experiments 6 S.E.M. Significance
between RA and NoRA treatments is given.
doi:10.1371/journal.pone.0049065.g003
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as day 12 in the NoRA condition. This effect is reproduced
(although to a lesser extend in the NoRA condition) by the A(d7–
d24) treatment. These results suggest that uPA inhibition by
amiloride leads to ECM accumulation in differentiating ESCs. We
can hypothesize that this effect is mediated by interference with
the uPA-plasmin-matrix metalloproteases cascade which induces
ECM degradation [33]. The early amiloride treatments A(d0–d3)
and A(d3–d7) have no significant effect on ECM deposition,
examined at day 24; whereas they augment collagen 1 deposition
at day 12. It is important to note that all the amiloride treatments
are equally inhibitor regarding adipocyte differentiation; therefore
it is possible that the collagen 1 regulation by amiloride contributes
to its effect on differentiation but is neither sufficient nor necessary.
Construction of an ESC Line Expressing Ectopically PAI-1
under an Inducible Control
In order to by-pass a potential effect of amiloride unrelated to
uPA inhibition, we undertook a genetic approach. We used
a sophisticated Tet-On inducible system adapted to mouse ESCs
described in Iacovino et al. [22]. Upon cre-lox recombination, the
mouse ESC line A2lox.cre, allows the reproducible targeting of
a locus on the X-chromosome, in the region upstream of the Hprt
gene, giving robust doxycycline-inducible expression of genes of
interest in both mESCs and differentiated cells.
We first analyzed the time-course expression of the endogenous
PA components in A2lox.cre ESCs before and after differentiation.
Similar results to what observed in CGR8 cells were obtained
(Data S5). The human PAI-1 cDNA was cloned into the targeting
vector and we isolated A2lox.cre ESC clones expressing human
PAI-1 after doxycycline induction. We further characterized the
clone 3 that expresses high levels of hPAI-1. As expected, clone 3
do not express human PAI-1 protein without doxycycline in-
duction, either intracellularly (not shown) or within its conditioned
medium, and before or after differentiation with or without RA
treatment (Fig. 5 A and B, black curves). By contrast, significant
human PAI-1 protein levels are constantly produced after
induction during the 24 days of the differentiation protocol
Figure 4. inhibition of uPA by amiloride treatments interfere with ESC adipogenesis. EBs from wild type CGR8 ES cells were induced to
differentiate and treated or not by 100 mM amiloride for different period of time: from days 0 to 24 [A], from days 0 to 3 [A(d0–d3)], from days 3 to 7
[A(d3–d7)], from days 7 to 14 [A(d7–d14)] or 24 [A(d7–d24)]. (A) Scheme of the different amiloride treatments. (B and C) ELISA assay
quantification of mouse activated uPA into the 24hrs conditioned medium of 106 cells RA-treated (C, adipogenic conditions) or not (B, skeletal
myogenic conditions) and treated or not by amiloride. (D to G) Effects of amiloride treatments on ESC adipogenesis. mRNAs from retinoic acid-
treated (adipogenic conditions) EBs were extracted and analyzed by real time RT-PCR for the expression of the adipogenic markers adiponectin (D),
aP2 (E) and PPARgamma (F). Results are expressed in arbitrary units, with the values of untreated CGR8 at day 24 taken as 1, and are the means 6
S.E.M. of at least 3 independent experiments. Significance to Ct values is given as: *P,0.05, **P,0.01 and ***P,0.001. (G) Adipocyte formation of
CGR8 treated or not by amiloride, as indicated, was visualized by Oil RedO staining, representative fields are shown.
doi:10.1371/journal.pone.0049065.g004
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(Fig. 5A and B, red curves). Importantly, in undifferentiated
ESCs and during the first 10 days of differentiation, whereas
endogenous mouse PAI-1 is not expressed (Fig. 5A and B, blue
curves), significant amounts of exogenous human PAI-1 protein
are produced. Activity of the exogenous human PAI-1 protein was
verified on supernatants at day 3 using a PAI-1 activity assay. No
activity was found in untreated cells, whereas a strong human PAI-
1 activity was detected in doxycycline treated cells (data not
shown), demonstrating that the secreted exogenous protein was
functional. We then evaluated the turnover of Dox-induced
human PAI-1 by quantifying by ELISA assay the remaining
protein at different time after doxycycline removal (Fig. 5C).
ESCs were treated with doxycycline either all the time or between
days 0 to 3 and hPAI-1 protein was analyzed until day 7. Starting
from a plateau at day 3, a similar PAI-1 protein amount is found at
day 4, 50% is found at day 5 and 25% at day 7. These results
suggest that the half-life of hPAI-1 protein in our cells is around
48 hrs.
PAI-1 Overexpression in A2lox.cre ESC Clone3 Decreases
ESC Adipogenesis
Doxycycline was applied during the differentiation of A2lox.cre
ESC clone3 in four different conditions: i) all the time of
differentiation, from days 0 to 24 [Dox], ii) only from days 0 to
3 [Dox(d0–d3)], iii) from days 3 to 7 [Dox(d3–d7)], iv) from
days 7 to 24 [Dox(d7–d24)] (Fig. 5D). The [Dox] and
[Dox(d7–d24)] treatments significantly decrease by 50% the
expression of adipogenic markers measured at day 24: adiponectin
(Fig. 5E), aP2 (Fig. 5F) and PPARgamma (Fig. 5G). By contrast
the [Dox(d0–d3)] and [Dox(d3–d7)] treatments have no effect.
These regulations of adipocyte formation are also detected after
Oil redO staining of the cultures (Fig. 5H).
uPA Inhibition or PAI-1 Overexpression Modulates
Successively Positively then Negatively ESC Skeletal
Myogenesis
In parallel experiments, we investigated the role of the PA
system in ESC skeletal myogenesis. The amiloride uPA inhibitor
was applied on CGR8 ESCs in the same conditions as for the
adipogenesis study (Fig. 4A). The [A] and [A(d7–d24)]
amiloride treatments of CGR8 cells strongly decrease the
expression of MyH1 and Myogenin skeletal muscle markers
measured at day 24 (Fig. 6A). Although to a lesser extent, the
[A(d3–d7)] treatment also inhibits skeletal myogenesis. Surpris-
ingly, we found that the [A(d0–d3)] treatment of CGR8 cells
leads to a 3.6 fold increase in expression of the MyH1 myogenic
marker, and a 2.6 fold increase in Myogenin expression (Fig. 6A).
Similar results are obtained by studying muscle proteins by
western blot analysis (Fig. 6B), immunofluorescence experiments
with anti-Myosin Heavy Chain1 antibodies (Fig. 6C), and flow
cytometry with anti-myogenin antibodies (Fig. 6D).
The effects of human PAI-1 overexpression on skeletal
myogenesis of A2lox.cre ESC clone3 were investigated by
applying doxycycline in the same conditions as for the adipogen-
esis study (Fig. 5D). Although less effective than in CGR8 ESCs,
myogenesis is readily detectable in A2lox.cre ESCs and in its
derivative clone3. We found results that parallel the effects of
amiloride on CGR8 cells: [Dox] and [Dox(d7–d24)] treatments
inhibit myogenesis, whereas [Dox(d0–d3)] activates it (Fig. 7).
The [Dox(d3–d7)] condition gives a modest activation of MyH1
and no effect on Myogenin expression (Fig. 7A).
Interfering with the PA system does neither affect neurogenesis
nor the other mesodermal ESC differentiations. Amiloride
treatments have no effect on neurogenesis (Data S6A) and
cardiomyogenesis (Data S6B) and doxycycline-induced over-
expression of human PAI-1 does not interfere with neurogenesis
(Data S6C), cardiomyogenesis (Data S6D,E), endothelial (Data
S6F, G, H) and smooth muscle (Data S6I) differentiations of
A2lox.cre mESC clone3. Particularly, interfering with the PA
system during the d0–d3 critical period did not affect these
differentiations.
PAI-12/2 Pluripotent Cells are Prone to Form Adipocytes
To investigate the effect of the absence of PAI-1 during ESC
differentiation we isolated and characterized pluripotent iPSCs
from PAI-12/2 mouse embryo fibroblasts (MEFs). Control MEFs
and MEFs knock-out for the PAI-1 gene [27] were transduced
with the reprogramming virus encoding the Klf4, Oct4, Sox2 and
c-Myc transcription factors together with GFP in a single poly-
cistronic transcript [28]. Several colonies presenting an ESC-like
phenotype (see an example in Data S7A) were cloned and
characterized for: i) mRNA and protein expression of the Nanog
and Oct4 pluripotent factors, which should be comparable to
ESC; ii) transgene extinction of gene expression -measured by
GFP expression and by specific primers-, which signs complete
epigenetic reprogrammation; and iii) in vitro and in vivo pluripotent
properties. Among the pluripotent factors, Nanog is not trans-
duced by the reprogramming vector; therefore its de novo
expression signs a reprogrammation process. As expected, the
analyzed colonies reached various degrees of reprogrammation;
only some of them are completely reprogrammed. An example of
this characterization is given in Fig. 8A and Data S7, S8, S9. To
confirm in vivo their pluripotent potential, ESCs, fully repro-
grammed control PAI-1+/+ and PAI-1 KO iPSCs (clone 3) were
injected subcutaneously into nude mice. Four animals were
injected for each cell line and tumours developed after four weeks
in all animals; sections of the different teratomas were histolog-
ically analyzed. All teratomas presented differentiated tissues
deriving from the three embryonic layers (Data S10).
We then chose to compare the in vitro differentiation potential of
both fully (clone 3) and partially (clone 1) reprogrammed PAI-1
KO iPSC clones to wild-type ESCs and fully reprogrammed
control PAI-1+/+ cells. We first checked, during the differentiation
process, the expression of known master genes of the ESC
commitment towards the embryonic cell lineages. We analyzed the
expression of Pax6 for the ectoderm (Fig. 8B), Sox17 for the
endoderm (Fig. 8B), Brachyury (Fig. 8B) Tbx1 and Mesp1 (Data
S11) for the mesoderm, and FoxA2 for the mesendoderm (Data
S11). Upon induction of ESC differentiation, the expression of
these genes is characterized by early peaks, variable between days
4 to 10, which are regulated by RA. As expected, the iPSCs+/+
gives an expression profile of these genes very similar to the wild
type CGR8 ESC control. Likewise, the partially reprogrammed
iPSC clone 1 gives aberrant level of expression and RA responses
in each case, demonstrating that its incomplete reprogrammation
interferes with its differentiation capacities. Interestingly, the fully
reprogrammed iPS PAI-1 KO clone 3 gives in majority similar
expression as wt ESCs and iPSCs, except for the ectoderm Pax6
and the mesoderm Tbx1 master genes.
We found no difference in the capacities of PAI-12/2 iPSCs to
form cardiomyocytes and myotubes (data not shown). By contrast,
at the opposite of control wild-type cells which necessitate an early
retinoic acid treatment to form adipocytes by day 24, the PAI-12/
2 iPSCs form adipocytes spontaneously and do not respond to the
retinoic acid treatment (Fig. 8C).
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Discussion
Regulation of proteolytic activity generated by the plasminogen
activation system is involved in many physiopathological pro-
cesses; in this study we demonstrate that it controls several distinct
and successive steps of the in vitro differentiation of embryonic stem
cells. We found that, during the terminal differentiation of ESCs,
either uPA inhibition or PAI-1 overexpression strongly and
concomitantly decrease adipogenesis and skeletal myogenesis.
Likewise, inhibitory effects were observed on adipogenesis when
interfering with the PA system during the early commitment of
ESCs. By contrast, skeletal myogenesis is stimulated by an early
uPA inhibition or PAI-1 overexpression. Although we cannot
exclude that tPA plays a role in ESC differentiation, we
reproduced most of the PAI-1 overexpression effects by inhibiting
uPA with amiloride, suggesting that, in our experimental model,
PAI-1 is mainly acting via inhibition of uPA. Interestingly these
regulations are specific to the adipogenic and skeletal myogenic
lineages; indeed neither endothelial cell formation, smooth muscle
myogenesis, cardiomyogenesis nor neurogenesis are affected.
The decrease of adipogenesis resulting from inhibition of uPA
or from PAI-1 overexpression, during the terminal differentiation
of ESCs is in agreement with the previous in vitro roles described
for uPA and PAI-1 in adipocyte differentiation [9]. It is also
consistent with in vivo data showing that PAI-12/2 mice are prone
to obesity [27]. Between days 0 to 7 of the differentiation protocol
of ESCs, embryoid bodies recapitulate the formation of the three
Figure 5. Doxycycline-induced human PAI-1 expression inhibits ESC adipogenesis of the A2lox.cre mESC clone3. (A and B) Retinoic
acid-treated (RA, panel B) or not (NoRA, panel A) EBs from A2lox.cre mESC clone3 cells treated (Dox, red lines) or not (Ct, black lines) by 0.5 mg/ml
of doxycycline were induced to differentiate and analyzed at various time, as indicated, between days 0 (d0) to 24 (d24). Endogenous mouse (mPAI-
1, blue lines) and ectopic human (hPAI-1) PAI-1 protein expressions in conditioned medium were quantified by ELISA technique. Values are given in
ng of PAI-1 amounts and expressed as means of at least three independent experiments 6 S.E.M. (C) Evaluation of the turnover of Dox-induced
intracellular human PAI-1 by ELISA after doxycycline removal. ESCs were treated with doxycycline either all the time (blue line) or between days 0 to 3
(red line) and hPAI-1 protein was analyzed until day 7. Values are given in ng of human PAI-1 amounts/mg of total proteins. Retinoic acid-treated EBs
from A2lox.cre mESC clone3 cells were induced to differentiate to adipocyte and treated or not by doxycycline for different period of time: from days
0 to 24 [Dox], from days 0 to 3 [Dox(d0–d3)], from days 3 to 7 [Dox(d3–d7)], from days 7 to 24 [Dox(d7–d24)]. (D) Scheme of the different
doxycycline treatments. (E to G) mRNAs were extracted and analyzed by real time RT-PCR for the expression of the adipogenic markers adiponectin
(E), aP2 (F) and PPARgamma (G). Results are expressed in arbitrary units, with the values of untreated A2lox.cre mESC clone3 cells at day 24 taken as
1, and are the means6 S.E.M. of at least 3 independent experiments. Significance to Ct values is given as: N.S. non significant, *P,0.05, **P,0.01 and
***P,0.001. (H) Adipocyte formation of A2lox.cre mESC clone3 cells treated or not, as indicated, by doxycycline was visualized by Oil RedO staining,
representative fields are shown.
doi:10.1371/journal.pone.0049065.g005
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embryonic germ layers. Interestingly, during this period, whereas
endogenous PAI-1 is not expressed, maximum uPA enzymatic
activity is detected. During this early period, we found that uPA
inhibition decreases adipogenesis. To explain these inhibitory
effects one could hypothesize that the PA system regulates ESC
differentiation by interfering with extracellular matrix deposition.
However our preliminary results show that even if the PA system
modulates collagen-1 deposition, there is no direct correlation
between this effect and the PA-mediated effects on ESC
adipogenesis. Interestingly, the PA system has also been implicated
in the activation of three major intracellular transduction path-
ways: ERK, PI3K/PKB and JAK/STAT pathways [34], them-
selves involved in adipogenesis. One can hypothesize that one or
several of these pathways are implicated in ESC differentiation in
response to the PA system. It has been already shown that PAI-1
prevents the cooperation of avb3 integrin with insulin signaling in
NIH3T3 fibroblasts, resulting in a decrease in insulin-induced
PKB phosphorylation [35]. Since, insulin is required for the
terminal step of differentiation of ESC towards adipocytes [30],
this pathway could be involved in the effects that we observed in
response to PA interference during ESC adipogenesis. Whether
the early (d0–d7) and late (d7–d24) effects are regulated by
common or different molecular mechanisms requires further
studies. However, it is very likely that they correspond to the
specific targeting of successive early precursors of the adipocyte
lineage. Indeed, despite the fact that such precursors have not be
precisely identified nor characterized, we know that PPARgamma,
the master gene of terminal adipocyte differentiation, is not
present before day 15 of ESC differentiation [30]. Therefore we
believe that the PA modulation of the ESC experimental model
could constitute a powerful tool to characterize the early
precursors of the adipogenic lineage. For example, our results
suggest that during the early period, one can specifically target the
adipocyte lineage by an amiloride treatment, potentially allowing
Figure 6. inhibition of uPA by amiloride treatments regulates ESC skeletal myogenesis. EBs from wild type CGR8 ES cells were induced to
differentiate to skeletal myotube and treated or not by 100 mM amiloride for different period of time as in figure 4. (A) mRNAs were extracted and
analyzed by real time RT-PCR for the expression of the skeletal myogenic markers MyH1 (left panel) and Myogenin (right panel). Results are expressed
in arbitrary units, with the values of untreated CGR8 at day 24 taken as 1, and are the means 6 S.E.M. of at least 3 independent experiments.
Significance to Ct values is given as: *P,0.05, **P,0.01 and ***P,0.001. (B) MyH1 protein expression at day 24 of differentiation of CGR8 cells
treated or not by amiloride, as indicated, was analyzed by Western blotting with anti-MyH1 (a-MyH1) antibodies. Membranes were reprobed with a-
ERK antibodies as loading control. (C) Myotube formation of CGR8 treated or not by amiloride, as indicated, was analyzed by immunofluorescence
experiments with anti-MyH1 antibodies (right panels) and nuclei were counterstained with DAPI (left panels), representative field are shown. (D)
Differentiated cells at day 24 were analyzed for Myogenin expression by flow cytometry, two different experiments are shown, controls giving either
28.7% (upper panels) or 16.2% (lower panels) myogenin positive cells.
doi:10.1371/journal.pone.0049065.g006
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the identification of important adipogenic genes differentially
regulated during this precise timing.
Though PAI-1 ectopic overexpression during ESC terminal
adipocyte differentiation gave similar inhibition than amiloride
treatment, intriguingly, early (d0–d7) overexpression during
differentiation has no effect on adipogenesis. To explain this lack
of effect one can hypothesize that, during the early steps of ESC
commitment, PAI-1 protein would lead to both adipogenic
inhibitory effects, via uPA enzymatic inhibition, and adipogenic
stimulatory effects, independently of uPA; resulting in the net
absence of effect on adipogenesis. Additional works are necessary
to further explore this hypothesis.
Finally the analysis of PAI-12/2 iPSCs constituted a third
converging argument to demonstrate the implication of the PA
system in ESC adipogenesis. Indeed, these cells are prone to form
adipocytes spontaneously and, contrarily to wild type cells, do not
respond anymore to the retinoic acid treatment. Furthermore,
these results fit with the observation that knock-out PAI-1 mice are
prone to obesity [27].
Regarding skeletal myogenesis and similarly to adipogenesis, we
found a decrease of differentiation resulting from uPA inhibition
or PAI-1 ectopic overexpression during the terminal differentia-
tion of ESCs. These results are in agreement with the previous
roles described for uPA and PAI-1 in in vitro muscle cell
differentiation [15] and in vivo skeletal muscle regeneration
[16,17]. Surprisingly, EB treated between days 0 to 3 presented
a significant increase in skeletal myogenesis compared to untreated
cells. The two approaches, uPA inhibition or PAI-1 overexpres-
sion, gave similar results. Because of the low expression level of the
proteases during this period, we did not expect an effect by
interfering with the PA. However, our results are consistent with
the fact that a robust enzymatic activity of uPA is effectively
detected at day 3. During this period uPA activity seems to
specifically repress skeletal myogenesis, demonstrating that the
commitment towards this particular mesodermal lineage can be
Figure 7. human PAI-1 expression regulates ESC skeletal myogenesis of A2lox.cre mESC clone3 after doxycycline induction. EBs
from A2lox.cre mESC clone3 cells were induced to differentiate to skeletal myotube and treated or not by doxycycline for different period of time as
in figure 5. (A) mRNAs were extracted and analyzed by real time RT-PCR for the expression of the skeletal myogenic markers MyH1 (left panel) and
Myogenin (right panel). Results are expressed in arbitrary units, with the values of untreated A2lox.cre mESC clone3 cells at day 24 taken as 1, and are
the means 6 S.E.M. of at least 3 independent experiments. Significance is given as: *P,0.05, **P,0.01 and ***P,0.001. (B) MyH1 protein expression
at day 24 of differentiation of A2lox.cre mESC clone3 cells treated or not by doxyxcycline, as indicated, was analyzed by Western blotting with anti-
MyH1 (a-MyH1) antibodies. Membranes were reprobed with a-ERK antibodies as loading control. (C) Myotube formation of A2lox.cre mESC clone3
cells treated or not by doxycycline, as indicated, was analyzed by immunofluorescence experiments with anti-MyH1 antibodies (right panels) and
counterstained with DAPI (left panels), representative fields are shown. (D) Differentiated cells at day 24 were analyzed for Myogenin expression by
flow cytometry.
doi:10.1371/journal.pone.0049065.g007
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modulated very early during differentiation. Whether interfering
with the PA system at that step, targets directly or indirectly
putative skeletal myogenic precursors needs to be investigated.
Interestingly, the expression of the transcription factors Pax3, Pax7
and MyoD that are known to be necessary during the early steps of
myogenesis, were undetectable at that time, appearing only after
day 14 of the differentiation protocol (data not shown); suggesting
that our effect targets earlier myogenic precursors.
Therefore, by pharmaceutical and genetic experiments we
found that early uPA inhibition, between days 0 to 3 of
differentiation, augments ESC myogenesis. To our knowledge,
this is the first time that such augmentation of in vitro myotube
formation in the mouse ESC model is described. Other ESC
myogenic stimulations described in the literature are limited to the
formation myogenic precursors, as for example, the treatment of
EBs with low doses of retinoic acid [36]. Since full skeletal
myogenesis from ESCs is a complex, long and difficult process to
reproduce in culture, especially within the human ESC model, we
believe that our results represent an important contribution in
order to fully differentiate ESCs towards this lineage.
Our results show that the PA system is capable to specifically
and concomitantly regulate two complex multi-steps ESC lineages,
adipocyte and skeletal muscle. Particularly, the very early opposite
regulation evidenced here, between days 0 to 3, could suggests
that, during that period, uPA activity induces a switch augment-
ing, on the one hand, adipogenesis and inhibiting, on the other
hand, skeletal myogenesis. This is reminiscent to a comparable
switch regulation between neurogenesis and cardiomyogenesis
induced by the p38MAPK that we already described in this model
[24]. To better understand the molecular mechanisms involved in
such switch, we need to identify the cellular precursors affected by
these processes.
Figure 8. characterization and adipogenic capacities of PAI-12/2 pluripotent cells. (A) In comparison to primary MEFs and wt CGR8 ESCs,
the degree of reprogrammation of wt and PAI-1 KO, clones 1 and 3, iPSCs was characterized by the mRNA levels of Oct4 and Nanog genes and by the
extinction of the expression of GFP gene. Results are expressed in arbitrary units, with the values of CGR8 mESCs taken as 1, and are the means 6
S.E.M. of at least 3 independent experiments. Significance is given as: *P,0.05, **P,0.01 and ***P,0.001. (B) Characterization, during the
differentiation process of iPSCs, of the expression of ESC commitment master genes. Retinoic acid-treated (RA) or not (NoRA) EBs from wild type
CGR8 ESCs and iPSC clones were induced to differentiate. mRNAs were extracted at various time, as indicated, and analyzed by real time RT-PCR for
the expression of Pax6, Sox17 and Brachyury. Results are expressed in arbitrary units, with the values of wild type CGR8 taken as 1, and are the means
6 S.E.M. of at least 3 independent experiments. (C) Retinoic acid-treated (RA) or not (NoRA) EBs from either wild type (WT) pluripotent cells or PAI-
12/2 iPSCs (PAI-1 KO) were induced to differentiate to adipocytes. mRNAs were extracted and analyzed by real time RT-PCR for the expression of the
adipogenic markers PPARgamma and adiponectin. Results are expressed in arbitrary units, with the values of WT NoRA condition at day 24 taken as 1,
and are the means 6 S.E.M. of at least 3 independent experiments. Significance is given as: N.S. non significant, *P,0.05, **P,0.01 and ***P,0.001.
doi:10.1371/journal.pone.0049065.g008
The PA System Modulates ESC Differentiation
PLOS ONE | www.plosone.org 12 November 2012 | Volume 7 | Issue 11 | e49065
Importantly, our results demonstrate that the simple interfer-
ence with the modulation of the extracellular matrix during ESC
differentiation is capable to commit ESC towards specific cell
lineages. These regulations taking place at the cellular membrane
and being reversible can be of great interest for the use of
committed ESCs in cellular therapy.
Supporting Information
Data S1 Immunocytochemistry analysis was performed
on CGR8 cells at day 24 of differentiation, using either
control antibodies (upper panels) or anti-PAI-1 antibo-
dies (lower panels). Photographs show representative fields of
differentiated cultures and arrows indicated either well differen-
tiated adipocytes (obtained in RA condition, left panel) or skeletal
myotubes (obtained in NoRA condition, right panel) stained by
PAI-1.
(TIF)
Data S2 intracellular inhibition of uPA by amiloride
treatments. Retinoic acid-treated (adipogenic conditions) or not
(skeletal myogenic conditions) EBs from wild type CGR8 ES cells
were induced to differentiate and treated or not by 100 mM
amiloride for different period of time, as indicated. Intracellular
mouse activated uPA and the inhibitory effects of amiloride
treatments were quantified by ELISA assay. Mean values of at
least three independent experiments are given.
(TIF)
Data S3 effects of amiloride treatments on collagen-1
secreted by ESCs induced to differentiate in adipogenic
conditions. Retinoic acid-treated (adipogenic conditions) EBs
from wild type CGR8 ES cells were induced to differentiate and
treated or not by 100 mM amiloride for different period of time, as
indicated. At day 12 (left panels) or 24 (right panels) cells were
removed and the extracellular matrix was examined by immuno-
fluorescence experiments using anti-collagen 1 antibodies. Photo-
graphs show representative fields.
(TIF)
Data S4 effects of amiloride treatments on collagen-1
secreted by ESCs induced to differentiate in myogenic
conditions. Non retinoic acid-treated (myogenic conditions) EBs
from wild type CGR8 ES cells were induced to differentiate and
treated or not by 100 mM amiloride for different period of time, as
indicated. At day 12 (left panels) or 24 (right panels) cells were
removed and the extracellular matrix was examined by immuno-
fluorescence experiments using anti-collagen 1 antibodies. Photo-
graphs show representative fields.
(TIF)
Data S5 mPAI-1 and uPA expression in wild type
A2lox.cre mESCs. (A and B) Retinoic acid-treated (RA) or
not (NoRA) EBs from A2lox.cre mESCs were induced to
differentiate and analyzed at various time, as indicated, between
days 0 (d0) to 24 (d24). Endogenous mouse (mPAI-1) PAI-1
protein expressions in conditioned medium (A) and cell lysates (B)
were quantified by ELISA technique at various time, as indicated,
between days 0 to 24. Values are given in ng of PAI-1 amounts
and expressed as means of at least three independent experiments
6 S.E.M. (C and D) Retinoic acid-treated (RA) or not (NoRA)
EBs from wild type CGR8 and A2lox.cre mESCs cells were
induced to differentiate and analyzed at day d14 (C) and day 24
(D). mRNAs were extracted and analyzed by real time RT-PCR
for the expression of uPA. Results are expressed in arbitrary units,
with the values of wild type CGR8 taken as 1, and are the means
6 S.E.M. of at least 3 independent experiments.
(TIF)
Data S6 amiloride treatments do not interfere with
either neurogenesis or cardiomyogenesis of CGR8 ESCs
and doxycycline-induced human PAI-1 expression does
not interfere with either neurogenesis, cardiomyogen-
esis, endothelial or smooth muscle differentiations of
A2lox.cre ESC clone3. (A and B) Retinoic acid-treated (A) or
not (B) EBs from wild type CGR8 ESCs were induced to
differentiate and treated or not by 100 mM amiloride for different
period of time: from days 0 to 12 [A], from days 0 to 3 [A(d0–
d3)], from days 3 to 7 [A(d3–d7)], from days 7 to 12 [A(d7–
d12)]. mRNAs were extracted and analyzed by real time RT-
PCR for the expression of the neuronal marker MAP2 (A) and for
the cardiomyocyte marker GATA4 (B). Results are expressed in
arbitrary units, with the values of untreated CGR8 at day 12 taken
as 1, and are the means 6 S.E.M. of at least 3 independent
experiments. (C, D and E) Retinoic acid-treated (C) or not (D and
E) EBs from A2lox.cre mESC clone3 cells were induced to
differentiate and treated or not by doxycycline for different period
of time: from days 0 to 12 [Dox], from days 0 to 7 [Dox(d0–
d7)], from days 7 to 12 [Dox(d7–d12)]. mRNAs were extracted
and analyzed by real time RT-PCR for the expression of the
neuronal marker MAP2 (C) and for the cardiomyocyte markers
GATA4 (D) and troponinT (E). Results are expressed in arbitrary
units, with the values of untreated A2lox.cre mESC clone3 cells at
day 12 taken as 1, and are the means 6 S.E.M. of at least 3
independent experiments. (F, G, H and I) EBs from A2lox.cre
mESC clone3 cells were induced to differentiate and treated
(Dox) or not (Ct) by doxycycline from days 0 to 12 and analyzed
at various time, as indicated, between days 0 to 12. mRNAs were
extracted and analyzed by real time RT-PCR for the expression of
the endothelial markers Flk1 (F), von Willebrand Factor (G) and
PECAM (H) for the smooth muscle marker a-SMA (I). Results are
expressed in arbitrary units, with the values of untreated A2lox.cre
mESC clone3 cells at day 3 taken as 1, and are the means 6
S.E.M. of at least 3 independent experiments.
(TIF)
Data S7 characterization of PAI-1+/+ and 2/2 iPSCs:
phenotype and transgene expression. (A) Photographs of
cell cultures at the undifferentiated state of: CGR8 wt ESCs (upper
left), iPSC wt clone (upper right), iPSC PAI-1 KO clone 3 (lower
left), iPSC PAI-1 KO clone 1 (lower right). Several typical packed
colonies with an ESC phenotype (red arrows) are visible on each
photograph. Pluripotent cells were grown on top of a feeder layer
which is composed of mitomycine-treated primary mouse embryo
fibroblasts (white arrows). (B) In comparison to primary MEFs and
wt CGR8 ESCs, the degree of reprogrammation of wt and PAI-1
KO, clones 1 and 3, iPSCs was characterized by the extinction of
the transgene expression. Results are expressed in arbitrary units,
with the values of CGR8 mESCs taken as 1, and are the means 6
S.E.M. of at least 3 independent experiments. Significance is given
as: *P,0.05. (C) Oct4 protein expression at the undifferentiated
state of CGR8 wt ESCs, iPSC wt clone, iPSC PAI-1 KO clone 3
and iPSC PAI-1 KO clone 1 was analyzed by Western blotting
with anti-Oct4 (a-Oct4) antibodies. Membranes were reprobed
with a-ERK antibodies as loading control.
(TIF)
Data S8 characterization of PAI-1+/+ and 2/2 iPSCs:
Nanog and Oct4 immunoflurescence. Immunofluorescence
staining of cell cultures at the undifferentiated state of: CGR8 wt
ESCs, iPSC wt clone, iPSC PAI-1 KO clone 3 and MEFs, as
indicated. Cells were labeled with anti-Nanog antibodies (upper
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panels) or anti-Oct4 antibodies (lower panels). Same microscope
fields labeled with DAPI are shown (right panels).
(TIF)
Data S9 characterization of PAI-1+/+ and 2/2 iPSCs:
Sox2 and SSEA1 immunofluorescence. Immunofluorescence
staining of cell cultures at the undifferentiated state of: CGR8 wt
ESCs, iPSC wt clone, iPSC PAI-1 KO clone 3 and MEFs, as
indicated. Cells were labeled with anti-Sox2 antibodies (upper
panels) or anti-SSEA1 antibodies (lower panels). Same microscope
fields labeled with DAPI are shown (right panels).
(TIF)
Data S10 histological characterization of PAI-1+/+ and
2/2 iPSC teratoma. CGR8 wt ESCs (A), iPSC wt clone (B), and
iPSC PAI-1 KO clone 3 (C) were injected subcutaneously into
nude mice. After four weeks, sections of the different teratomas
were histologically analyzed. All teratomas presented differentiated
tissues deriving from the three embryonic layers. Representative
fields of well-differentiated tissues are shown. Arrows indicate
examples of the three germ layer derivative structures: Cart =
cartilage (mesoderm derivative), Epit = ciliated epithelium
(endoderm derivative), and neural structures (ectoderm derivative):
neural rosettes and nerve fibers.
(TIF)
Data S11 characterization of PAI-1+/+ and 2/2 iPSCs:
in vitro differentiation. Characterization of the expression of
ESC commitment master genes during the differentiation process
of iPSCs. Retinoic acid-treated (RA) or not (NoRA) EBs from wild
type CGR8 ESCs and iPSC clones were induced to differentiate.
mRNAs were extracted at day 10 and analyzed by real time RT-
PCR for the expression of FoxA2, Mesp1 and Tbx1. Results are
expressed in arbitrary units, with the values of wild type CGR8 at
day 0 taken as 1, and are the means 6 S.E.M. of at least 3
independent experiments.
(TIF)
Data S12 Forward and reverse primer sequences of the
various genes analyzed by real-time RT-PCR.
(TIF)
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